Current Status on Clinical Therapy for Advanced Gastric Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XIE Naichang , LIN Jinling.

Department of General Surgery, The First Affiliated Hospital, Guangxi Medical University, Nanning 530021, China;

Corresponding author：

Keywords：

Advanced gastric carcinoma Comprehensive therapy Operation Prognosis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【Abstract】ObjectiveTo discuss how to improve the current status on clinical therapy for advanced gastric carcinoma.
MethodsRelated literatures searched on Medline were collected and reviewed.
ResultsThe 5th edition of UICC/AJCC TNM staging system of gastric carcinoma is useful to evaluate the prognosis of patients with advanced gastric carcinoma followed by extended lymphadenectomy. There are many factors influencing their prognosis including disease stage, extent of lymphadenectomy, assistant therapy and so on.
ConclusionIt is significant for patients with advanced gastric carcinoma to undergo individualized extended lymphadenectomy and comprehensive therapy to improve their prognosis after radical gastrectomy

Citation： XIE Naichang,LIN Jinling.. Current Status on Clinical Therapy for Advanced Gastric Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2006, 13(1): 52-55. doi: Copy

1.	Ichikura T, Ogawa T, Chochi K, et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma [J]. World J Surg, 2003; 27(3)∶330.
2.	Kikuchi S, Katada N, Sakuramoto S, et al. Factors associated with pN3 stage tumors according to the TNM classification in advanced gastric cancer [J]. Hepatogastroenterology, 2003; 50(53)∶1723.
3.	Nitti D, Marchet A, Olivieri M, et al. Lymphadenectomy in patients with gastric cancer. A critical review [J]. Suppl Tumori, 2003; 2(5)∶S35.
4.	Roviello F, Marrelli D, Morgagni P, et al. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study [J]. Ann Surg Oncol, 2002; 9(9)∶894.
5.	Edwards P, Blackshaw GR, Lewis WG, et al. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma [J]. Br J Cancer, 2004; 90(10)∶1888.
6.	Verreet PR. Stageadapted radical principles in gastric carcinoma [J]. Schweiz Rundsch Med Prax, 1998; 87(13)∶447.
7.	Roviello F, Marrelli D, Morgagni P, et al. Benefits of extended lymphadenectomy in patients with gastric carcinoma with metastasis to second level lymph nodes. An Italian multicenter study [J]. Chir Ital, 2003; 55(4)∶491.
8.	Ikeguchi M, Oka S, Gomyo Y, et al. Prognostic benefit of extended radical lymphadenectomy for patients with gastric cancer [J]. Anticancer Res, 2000; 20(2B)∶1285.
9.	Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial [J]. J Clin Oncol, 2004; 22(11)∶2069.
10.	Maruyama K, Sasako M, Kinoshita T, et al. Reasonable lymph node dissection in radical gastrectomy for gastric cancer: introduction of computer information system and lymphography technique by Indiaink [J]. Nippon Geka Gakkai Zasshi, 1989; 90(9)∶1318.
11.	Maruyama K, Gunven P, Okabayashi K, et al. Lymph node metastases of gastric cancer. General pattern in 1 931 patients [J]. Ann Surg, 1989; 210(5)∶596.
12.	Omejc M, Mekicar J. Role of computer analysis in gastric cancer surgery: evaluation of the WinEstimate v. 2.5 computer program [J]. World J Surg, 2004; 28(1)∶59.
13.	Ohta K, Nishi M, Nakajima T, et al. Indications for total gastrectomy combined with pancreaticosplenectomy in the treatment of middle gastric cancer [J]. Nippon Geka Gakkai Zasshi, 1989; 90(9)∶1326.
14.	Kikuchi S, Nemoto Y, Natsuya K, et al. Which patients with advanced, proximal gastric cancer benefit from complete clearance of splenopancreatic lymph nodes? [J]. Anticancer Res, 2002; 22(6B)∶3513.
15.	Marrelli D, Roviello F, de Manzoni G, et al. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study [J]. World J Surg, 2002; 26(9)∶1160.
16.	Shiraishi N, Inomata M, Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses [J]. Cancer, 2000; 89(2)∶255.
17.	Funami Y, Tokumoto N, Miyauchi H, et al. Prognostic value of peritoneal lavage cytology and chemotherapy during surgery for advanced gastric cancer [J]. Int Surg, 1999; 84(3)∶220.
18.	Sethna KS, Sugarbaker PH. New prospects for the control of peritoneal surface dissemination of gastric cancer using perioperative intraperitoneal chemotherapy [J]. Cancer Therapy, 2004; 2（A）∶79.
19.	Marutsuka T, Shimada S, Shiomori K, et al. Mechanisms of peritoneal metastasis after operation for nonserosainvasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis [J]. Clin Cancer Res, 2003; 9(2)∶678.
20.	Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study [J]. Hepatogastroenterology, 2001; 48(42)∶1776.
21.	梁寒，王仆，王晓娜，等. 活性碳吸附丝裂霉素C腹腔化疗预防进展期胃癌术后复发 [J]. 中华外科杂志, 2003; 41(4)∶274.
22.	Newman E, Marcus SG, Potmesil M, et al. Neoadjuvant chemotherapy with CPT11 and cisplatin downstages locally advanced gastric cancer [J]. J Gastrointest Surg， 2002; 6(2)∶212.
23.	Ajani JA, Mansfield PF, Janjan N, et al. Multiinstitutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma [J]. J Clin Oncol， 2004; 22(14)∶2774.
24.	Kim JP, Yu HJ, Lee JH. Results of immunochemosurgery for gastric carcinoma [J]. Hepatogastroenterology， 2001; 48(41)∶1227.
25.	Nakahara S, Tsunoda T, Baba T, et al. Dendritic cells stimulated with a bacterial product, OK432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide [J]. Cancer Res， 2003; 63(14)∶4112.
26.	Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumorassociated lymphocytes in patients with advanced gastric cancer: a randomized trial [J]. Clin Cancer Res， 2002; 8(6)∶1767.
27.	Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER2/neuderived peptides can induce specific Tcell responses in patients with gastric cancer [J]. Clin Cancer Res， 2002; 8(11)∶3394.

1. Ichikura T, Ogawa T, Chochi K, et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma [J]. World J Surg, 2003; 27(3)∶330.
2. Kikuchi S, Katada N, Sakuramoto S, et al. Factors associated with pN3 stage tumors according to the TNM classification in advanced gastric cancer [J]. Hepatogastroenterology, 2003; 50(53)∶1723.
3. Nitti D, Marchet A, Olivieri M, et al. Lymphadenectomy in patients with gastric cancer. A critical review [J]. Suppl Tumori, 2003; 2(5)∶S35.
4. Roviello F, Marrelli D, Morgagni P, et al. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study [J]. Ann Surg Oncol, 2002; 9(9)∶894.
5. Edwards P, Blackshaw GR, Lewis WG, et al. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma [J]. Br J Cancer, 2004; 90(10)∶1888.
6. Verreet PR. Stageadapted radical principles in gastric carcinoma [J]. Schweiz Rundsch Med Prax, 1998; 87(13)∶447.
7. Roviello F, Marrelli D, Morgagni P, et al. Benefits of extended lymphadenectomy in patients with gastric carcinoma with metastasis to second level lymph nodes. An Italian multicenter study [J]. Chir Ital, 2003; 55(4)∶491.
8. Ikeguchi M, Oka S, Gomyo Y, et al. Prognostic benefit of extended radical lymphadenectomy for patients with gastric cancer [J]. Anticancer Res, 2000; 20(2B)∶1285.
9. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial [J]. J Clin Oncol, 2004; 22(11)∶2069.
10. Maruyama K, Sasako M, Kinoshita T, et al. Reasonable lymph node dissection in radical gastrectomy for gastric cancer: introduction of computer information system and lymphography technique by Indiaink [J]. Nippon Geka Gakkai Zasshi, 1989; 90(9)∶1318.
11. Maruyama K, Gunven P, Okabayashi K, et al. Lymph node metastases of gastric cancer. General pattern in 1 931 patients [J]. Ann Surg, 1989; 210(5)∶596.
12. Omejc M, Mekicar J. Role of computer analysis in gastric cancer surgery: evaluation of the WinEstimate v. 2.5 computer program [J]. World J Surg, 2004; 28(1)∶59.
13. Ohta K, Nishi M, Nakajima T, et al. Indications for total gastrectomy combined with pancreaticosplenectomy in the treatment of middle gastric cancer [J]. Nippon Geka Gakkai Zasshi, 1989; 90(9)∶1326.
14. Kikuchi S, Nemoto Y, Natsuya K, et al. Which patients with advanced, proximal gastric cancer benefit from complete clearance of splenopancreatic lymph nodes? [J]. Anticancer Res, 2002; 22(6B)∶3513.
15. Marrelli D, Roviello F, de Manzoni G, et al. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study [J]. World J Surg, 2002; 26(9)∶1160.
16. Shiraishi N, Inomata M, Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses [J]. Cancer, 2000; 89(2)∶255.
17. Funami Y, Tokumoto N, Miyauchi H, et al. Prognostic value of peritoneal lavage cytology and chemotherapy during surgery for advanced gastric cancer [J]. Int Surg, 1999; 84(3)∶220.
18. Sethna KS, Sugarbaker PH. New prospects for the control of peritoneal surface dissemination of gastric cancer using perioperative intraperitoneal chemotherapy [J]. Cancer Therapy, 2004; 2（A）∶79.
19. Marutsuka T, Shimada S, Shiomori K, et al. Mechanisms of peritoneal metastasis after operation for nonserosainvasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis [J]. Clin Cancer Res, 2003; 9(2)∶678.
20. Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study [J]. Hepatogastroenterology, 2001; 48(42)∶1776.
21. 梁寒，王仆，王晓娜，等. 活性碳吸附丝裂霉素C腹腔化疗预防进展期胃癌术后复发 [J]. 中华外科杂志, 2003; 41(4)∶274.
22. Newman E, Marcus SG, Potmesil M, et al. Neoadjuvant chemotherapy with CPT11 and cisplatin downstages locally advanced gastric cancer [J]. J Gastrointest Surg， 2002; 6(2)∶212.
23. Ajani JA, Mansfield PF, Janjan N, et al. Multiinstitutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma [J]. J Clin Oncol， 2004; 22(14)∶2774.
24. Kim JP, Yu HJ, Lee JH. Results of immunochemosurgery for gastric carcinoma [J]. Hepatogastroenterology， 2001; 48(41)∶1227.
25. Nakahara S, Tsunoda T, Baba T, et al. Dendritic cells stimulated with a bacterial product, OK432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide [J]. Cancer Res， 2003; 63(14)∶4112.
26. Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumorassociated lymphocytes in patients with advanced gastric cancer: a randomized trial [J]. Clin Cancer Res， 2002; 8(6)∶1767.
27. Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER2/neuderived peptides can induce specific Tcell responses in patients with gastric cancer [J]. Clin Cancer Res， 2002; 8(11)∶3394.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Current Status on Clinical Therapy for Advanced Gastric Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content